- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05233618
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSCT 002)
Phase I Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ Acute Myeloid Leukemia, Myelofibrosis and Chronic Myelomonocytic Leukemia
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Danyelle Coley
- Phone Number: 14349825027
- Email: JCS6RZ@uvahealth.org
Study Contact Backup
- Name: Samantha Brooks
- Phone Number: 4349823365
- Email: SNB3GC@uvahealth.org
Study Locations
-
-
Virginia
-
Charlottesville, Virginia, United States, 22901
- Recruiting
- Danyelle Coley
-
Contact:
- Danyelle Coley
- Phone Number: 434-982-5027
- Email: JCS6RZ@uvahealth.org
-
Contact:
- Samantha Brooks
- Phone Number: 4345541718
- Email: SNB3GC@uvahealth.org
-
Principal Investigator:
- Karen Ballen, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The patient is ≥18 years old and ≤ 75 years old.
- The patient has a life expectancy of >6 months.
- The patient has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2.
The patient has adequate baseline organ function, including cardiac, renal, and hepatic function within 28 days of start of therapy:
- Left ventricular ejection fraction (LVEF) ≥ 50% as measured by multigated acquisition scan (MUGA) or 2-dimensional (2-D) echocardiogram (ECHO) and no clinically significant abnormalities on a 12-lead electrocardiogram (ECG)
- Serum Creatinine ≤ 1.5 mg/dL
- Bilirubin ≤1.5 mg/dL
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 times the upper limit of normal (ULN)
- Absolute neutrophil count (ANC) ≥0.5 × 10⁹/L
- Platelets ≥ 80,000/mm^3
- Serum albumin ≥3.2 (note that albumin infusions are not permitted in order to enable eligibility)
Patient meets the 2016 WHO diagnostic criteria for MF, is CD 123+, and has an IPSS/DIPSS/DIPSS-plus intermediate-1 with anemia (Hb < 10g/dl), splenomegaly (> 12 cm), leukocytosis (WBC > 25K) intermediate-2 or high-risk disease pre transplant.
Or
Patient has a 2016 WHO-defined diagnosis of CMML (persistent monocytosis ≥1 × 10⁹/L for at least 3 months, with other causes excluded, and monocytes ≥10% of WBC in peripheral blood, no criteria and no previous history of CML, ET, PV, and acute promyelocytic leukemia) pre transplant and is CD123+
Or
Patient has 2016 WHO-defined CMML-1 (2-4% blasts in peripheral blood and/or 5-9% blasts in bone marrow) and CMML-2 (5-19% blasts in peripheral blood and/or 10-19% blasts in bone marrow, and/or presence of Auer rods) pre transplant and is CD 123+
Or
Patient has CD 123+ AML in morphologic remission pre transplant
- Receipt of first allogeneic stem cell transplant (related, unrelated, haploidentical or cord blood) 60-120 days prior to study registration
- Patient is in morphologic remission post-HCT and at the time of study registration
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- For females and males of reproductive potential: agreement to use adequate contraception for at least one month prior to screening, during study participation and for an additional one week after the end of study drug administration. Other (non-study) medications may require participants to use adequate contraception for longer.
- For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner. Other (non-study) medications may require participants to use adequate contraception for longer.
- Agreement to adhere to Lifestyle Considerations throughout study duration
Exclusion Criteria:
- Treatment with any disease-related therapy, including radiation therapy or investigational agent, within 14 days of study entry
- Previous treatment with tagraxofusp or known hypersensitivity to any components of the drug product
- Active malignancy and/or cancer history (excluding myeloproliferative disorders and concomitant myeloid malignancies as specified in the inclusion criteria) that can confound the assessment of the study endpoints. Patients with a past cancer history (within 2 years of entry) and/or ongoing active malignancy or substantial potential for recurrence must be discussed with the Sponsor before study entry. Patients with the following neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ (including superficial bladder cancer), cervical intraepithelial neoplasia, or organ-confined prostate cancer with no evidence of progressive disease.
- Known active or suspected disease involvement of the central nervous system (CNS)
- Receiving > 10 mg prednisone daily for GVHD
- Overall Grade 2 or greater acute GVHD (per Magic criteria) at time of registration
- Pregnant or breast feeding
- Requirement of supplemental oxygen
- Clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction or stroke within 6 months of study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication)
- Uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, pulmonary hypertension) that in the opinion of the Investigator would put the patient at significant risk for pulmonary complications during the study
- Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, disseminated intravascular coagulation, or psychiatric illness/social situations that would limit compliance with study requirements
- Known positive status for human immunodeficiency virus or active or chronic Hepatitis B or Hepatitis C
- Receiving treatment for known or suspected fungal infection (prophylaxis is acceptable)
- Known positive SARS-COV-2 test within 3 weeks of study entry. Exception: Tests that reflect past, resolved infection where the patient is determined to NOT be infectious, according to an infectious disease specialist, do not exclude the patient from participation.
- Pedal edema ≥ grade 2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tagraxofusp (escalating doses)
IV tagraxofusp on days 1-3 of cycles 1-4 and days 1-2 of additional cycles for up to 9 cycles (some participants could receive more if considered in their best interest)
|
inpatient on days 1-3 of cycles 1-4 and days 1-2 of additional cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and severity of grade ≥ 3 adverse events
Time Frame: Through about 30 days following last infusion of tagraxofusp
|
Severity is based upon CTCAE v5 criteria.
|
Through about 30 days following last infusion of tagraxofusp
|
Dose limiting toxicities
Time Frame: During cycles 1 and 2 (each cycle is 28 days) of study treatment for each participant
|
Frequencies of certain, more severe, types of side effects from the study drug
|
During cycles 1 and 2 (each cycle is 28 days) of study treatment for each participant
|
Percent of planned tagraxofusp dose received
Time Frame: Through cycle 4 (each cycle is 28 days) of study treatment for each participant
|
During cycles 1-4 only
|
Through cycle 4 (each cycle is 28 days) of study treatment for each participant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time from HCT to relapse and death or last contact.
Time Frame: Participants will be followed through 2 years after date of HCT
|
Duration
|
Participants will be followed through 2 years after date of HCT
|
Frequency and severity of acute GVHD grades II-IV and chronic GVHD
Time Frame: Participants will be followed through 2 years after date of HCT
|
Mild, moderate or severe per Magic criteria
|
Participants will be followed through 2 years after date of HCT
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Karen Ballen, UVA
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Disease Attributes
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Myelodysplastic-Myeloproliferative Diseases
- Chronic Disease
- Primary Myelofibrosis
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
Other Study ID Numbers
- HSR210434
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Kronos BioActive, not recruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States, Spain
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
Clinical Trials on Tagraxofusp
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruitingAcute Myeloid LeukemiaItaly
-
Stemline Therapeutics, Inc.CompletedMyelofibrosis | Chronic Myelomonocytic LeukemiaUnited States, Canada
-
Stemline Therapeutics, Inc.TerminatedAcute Myeloid LeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBlastic Plasmacytoid Dendritic Cell NeoplasmUnited States
-
Joshua ZeidnerUniversity of North Carolina, Chapel Hill; Stemline Therapeutics, Inc.Not yet recruiting
-
Sidney Kimmel Comprehensive Cancer Center at Johns...StemlineTherapeutics, Inc.RecruitingAcute Myeloid LeukemiaUnited States
-
M.D. Anderson Cancer CenterRecruitingChronic Myelomonocytic Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Chronic Myelomonocytic Leukemia-1 | Chronic Myelomonocytic Leukemia-2United States
-
Jonsson Comprehensive Cancer CenterStemline Therapeutics, Inc.WithdrawnAcute Myeloid LeukemiaUnited States
-
Stemline Therapeutics, Inc.TerminatedMultiple MyelomaUnited States
-
Therapeutic Advances in Childhood Leukemia ConsortiumRecruitingLymphoma, B-Cell | Hodgkin Lymphoma | Lymphoblastic Lymphoma | Lymphoma, T-Cell | AML | Hematologic Malignancy | MDS | Acute Undifferentiated Leukemia | ALL | Mixed Phenotype Acute Leukemia | BPDCNUnited States, Australia